X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New report shows more than 260 medicines in development to fight neurodegenerative diseases

By Andrew Powaleny  |    October 12, 2021
With neurodegenerative diseases affecting millions of individuals in the United States, now is an important time to spotlight the increasing impact these diseases have on our country’s aging...   Read More

How research evolves and brings new hope to patients

By Stephen J. Ubl  |    June 11, 2021
Before medicines can be made available to patients, they often begin as ideas that are based on newly discovered molecules and cells, strange phenomena or little-understood processes in the body....   Read More

Continued R&D into Alzheimer’s disease means hope for patients, families and caregivers

By Richard Moscicki, M.D.  |    June 4, 2021
More than 6 million Americans, most of them age 65 or older, live with Alzheimer’s disease, a devastating degenerative brain disease and the most common form of dementia. After heart disease and...   Read More

Guest Post: Honoring Hispanic Heritage Month by taking action on health equity

By Guest Contributor  |    October 12, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. Today, we are pleased to...   Read More

Speaker Pelosi’s drug pricing plan could result in 56 fewer new medicines over 10 years

By Juliet Johnson  |    November 21, 2019
A new analysis from economic consulting firm Vital Transformation shows that Speaker Nancy Pelosi’s drug pricing plan, H.R.3, could result in at least 56 fewer innovative medicines for patients...   Read More

New report details the setbacks and challenges to Alzheimer’s research

By Gretta Stone  |    September 12, 2018
Illustrating the challenges of developing medicines to fight Alzheimer’s disease, a new analysis found that between 1998 and 2017, there were 146 unsuccessful medicines in clinical trials for...   Read More

Disrupting Alzheimer's

By Andrew Powaleny  |    September 10, 2018
We are living in a new era of medicine, where treatments and even cures once believed to be impossible are today a reality. But this immense progress does not apply universally and there have been...   Read More

A new era in Alzheimer’s innovation

By Andrew Powaleny  |    April 19, 2018
After heart disease and cancer, Alzheimer’s disease and dementia are the leading cause of death for seniors, responsible for one out of every three deaths. Today, the disease devastates the minds...   Read More

New report shows over 500 medicines in development for neurological disorders

By Andrew Powaleny  |    April 18, 2018
Neurological disorders, which include more than 1,000 conditions that disrupt the brain and nervous system, affect an estimated 100 million Americans, nearly one third of the U.S. population....   Read More

ICYMI – Report highlights increasing prevalence for Alzheimer’s disease

By Andrew Powaleny  |    December 11, 2017
The number of Americans affected by Alzheimer’s disease (AD) continues to rise according to a new report.1 Researchers found that approximately 6.08 million Americans had Alzheimer’s or mild...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates